CancerNCT07027449
Connecting People With Cancer to Employment Support
A study testing Screening and Referral Workflow in people with Cancer, run by University of Kansas Medical Center.
Trial summary
The goal of this clinical trial is to learn if a clinical workflow that screens adult patients with cancer for challenges at work and refers them to supportive resources is feasible, appropriate, and acceptable to patients and staff members in 2 cancer care settings. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Screening and Referral Workflow
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- Jan 2028to Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Eligible Patients:
- visiting a participating medical or radiation oncology clinic for new diagnosis, treatment, or follow-up of any type of cancer;
- employed at the time of cancer diagnosis;
- age 18 or older;
- able to give full informed consent;
- able to communicate in English or Spanish.
Eligible Staff:
- age 18 or older;
- employed at one of the participating clinical sites.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Implementing Pathways to Identify and Address Employment Concerns Among People With Cancer Across Diverse Clinical Settings
The goal of this clinical trial is to learn if a clinical workflow that screens adult patients with cancer for challenges at work and refers them to supportive resources is feasible, appropriate, and acceptable to patients and staff members in 2 cancer care settings. The main questions it aims to answer are:
Is the clinical workflow feasible and acceptable to participants? Are study procedures feasible and acceptable to participants?
Patient participants will complete 2 surveys: 1 at the time of enrollment and 1 six months later.
Read the detailed description
Investigators will conduct a prospective single-arm study at 2 sites to pilot and iteratively adapt a clinical workflow intervention, implementation strategies, and associated study procedures. Investigators will implement the clinical workflow intervention across each study site, then recruit consecutive patients (n=50) to complete patient-reported measures at 2 time points (T1: enrollment; T2: 6-month follow-up. Investigators will recruit staff members (n=20) to complete survey measures at 2 time points (T1: beginning of pilot study period; T2: end of pilot study period).
- Conditions
- Cancer
- Being tested
- Screening and Referral Workflow
- Keywords
- employment, social needs, screening
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Screening and Referral WorkflowBehavioural
The Screening and Referral Workflow intervention will include screening eligible patients for employment-related needs and referring those who require support to community-based employment resources.
| Study group | Role | What they receive |
|---|---|---|
| Screening and Referral Workflow | Experimental | Not described Receives: Behavioral: Screening and Referral Workflow |
What is being measured
The primary outcome is the main question the study is designed to answer.
Enrollment Rate
T1 survey enrollment rate among eligible patients and staff
Measured: Baseline
Follow-up Survey Completion Rate
Rate of study survey completion within 18 days of the 6-month follow-up timepoint
Measured: 6 months
Staff-reported Feasibility of Intervention
Proportion of staff disagreeing with one or more Feasibility of Intervention Measure items
Measured: Approximately 9 months
Acceptability of Intervention: Staff
Proportion of staff disagreeing with one or more Acceptability of Intervention Measure items
Measured: Approximately 9 months
Acceptability of Intervention: Patients
Proportion of patients providing negative ratings for one or more Theoretical Framework of Acceptability questionnaire items
Measured: Baseline; 6 months
Employment Concerns Screening
Proportion of eligible patients screened for employment concerns
Measured: Baseline
Secondary outcomes (6)
Employment status
Patient-reported employment status using the US Census Bureau's American Community Survey employment status items
Measured: Baseline; 6 months
Sick leave duration
Patient-reported sick leave duration reported in days
Measured: Baseline; 6 months
Health-related quality of life
Patient-reported quality of life using the EQ-5D-5L scale. Scores range 1-5, with higher scores indicating poorer quality of life (worse outcome).
Measured: Baseline; 6 months
Health insurance status
Patient-reported health insurance status using the US Census Bureau's American Community Survey health insurance status items
Measured: Baseline; 6 months
Self-efficacy
Patient-reported self-efficacy using the General Self-Efficacy Scale. Scores range 10-40, with higher scores indicating more self-efficacy (better outcome).
Measured: Baseline; 6 months
Financial toxicity
Patient-reported financial toxicity using the COST measure. Scores range 0-48, with higher scores indicating more financial toxicity (worse outcome).
Measured: Baseline; 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2025
- Study startJan 2028 (estimated)
- Primary completionJun 2029 (estimated)
- Study completionJun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of Kansas Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Kansas Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rachel C. Forcino, PhD, MSc, Principal investigator, University of Kansas Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07027449
- Sponsor's protocol ID
- STUDY00161657
- Status last verified
- Jun 2025
- First submitted
- 27 May 2025
- Last updated
- 18 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementing Pathways to Identify and Address Employment Concerns Among People With Cancer Across Diverse Clinical Settings
- ClinicalTrials.gov ID
- NCT07027449
- Acronym / sponsor ID
- STUDY00161657
- Conditions
- Cancer
- Keywords
- employment, social needs, screening
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University of Kansas Medical CenterUniversity, hospital or other
- Study start
- Jan 2028 (estimated)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- Jun 2029 (estimated)
- First posted
- 18 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a clinical workflow that screens adult patients with cancer for challenges at work and refers them to supportive resources is feasible, appropriate, and acceptable to patients and staff members in 2 cancer care settings. The main questions it aims to answer are:
Is the clinical workflow feasible and acceptable to participants? Are study procedures feasible and acceptable to participants?
Patient participants will complete 2 surveys: 1 at the time of enrollment and 1 six months later.
Detailed description
Investigators will conduct a prospective single-arm study at 2 sites to pilot and iteratively adapt a clinical workflow intervention, implementation strategies, and associated study procedures. Investigators will implement the clinical workflow intervention across each study site, then recruit consecutive patients (n=50) to complete patient-reported measures at 2 time points (T1: enrollment; T2: 6-month follow-up. Investigators will recruit staff members (n=20) to complete survey measures at 2 time points (T1: beginning of pilot study period; T2: end of pilot study period).
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Screening and Referral Workflow | Experimental | Behavioral: Screening and Referral Workflow |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Screening and Referral WorkflowThe Screening and Referral Workflow intervention will include screening eligible patients for employment-related needs and referring those who require support to community-based employment resources. | Behavioural | Screening and Referral Workflow |
Primary outcome
Enrollment Rate
Time frame: Baseline
T1 survey enrollment rate among eligible patients and staff
Follow-up Survey Completion Rate
Time frame: 6 months
Rate of study survey completion within 18 days of the 6-month follow-up timepoint
Staff-reported Feasibility of Intervention
Time frame: Approximately 9 months
Proportion of staff disagreeing with one or more Feasibility of Intervention Measure items
Acceptability of Intervention: Staff
Time frame: Approximately 9 months
Proportion of staff disagreeing with one or more Acceptability of Intervention Measure items
Acceptability of Intervention: Patients
Time frame: Baseline; 6 months
Proportion of patients providing negative ratings for one or more Theoretical Framework of Acceptability questionnaire items
Employment Concerns Screening
Time frame: Baseline
Proportion of eligible patients screened for employment concerns
6 secondary outcomes
Employment status
Time frame: Baseline; 6 months
Sick leave duration
Time frame: Baseline; 6 months
Health-related quality of life
Time frame: Baseline; 6 months
Health insurance status
Time frame: Baseline; 6 months
Self-efficacy
Time frame: Baseline; 6 months
Financial toxicity
Time frame: Baseline; 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rachel C. Forcino, PhD, MSc principal investigator
University of Kansas Medical Center
Questions about this trial
What is this clinical trial studying?
A study testing Screening and Referral Workflow in people with Cancer, run by University of Kansas Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rachel C. Forcino, PhD, MSc (913-588-4742, rforcino@kumc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Enrollment Rate (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2025.